Andrew Penkethman – Managing Director and CEO – Ardea Resources (ASX:ARL) is advancing its flagship 100%-owned Kalgoorlie Nickel Project (KNP). KNP is the largest Nickel–Cobalt resource in Australia and in the top 10 globally, making it of a scale that is incredibly rare and important in the World’s journey to Net Zero. KNP was awarded Major Project Status by the Australian Federal Government, recognising the national and strategic significance of the KNP to the Australian economy and the Eastern Goldfields of Western Australia.
Copyright 2024 – Finance News Network
25 Oct 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
09 March 2023 - Knosys Limited (ASX:KNO) Managing Director John Thompson discusses drivers of revenue growth, the roadmap for the company's three SaaS solutions, onshoring GreenOrbit operations and outlook for the second half.
30 Jul 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases.
04 Nov 2019 - Altura Mining (ASX:AJM) Managing Director James Brown, talks about its rights issue to raise $21M, production at its Pilgangoora mine in the Pilbara and outlook for lithium demand.
20 Mar 2024 - Dotz Nano Limited (ASX:DTZ) CEO Sharon Malka discusses development of Dotz Earth, a new-generation sorbent technology for carbon dioxide capture.
30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
15 Jul 2020 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company's synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.
30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
